Loroblis, 16 tablets, Innergy

Streptococcus salivarius K12 is a bacterial strain that colonizes the oral cavity and nasopharynx of healthy individuals and is part of the normal bacterial flora.

It restores eubiosis in the oral cavity, oropharynx and nasopharynx. Streptococcus salivarius K12 produces 2 bacteriocins that have the potential to inhibit the development of pathogenic bacterial strains (e.g.: Streptococcus pyogenes, Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis, responsible for bacterial pharyngitis and tonsillitis, acute otitis media and halitosis). Streptococcus salivarius K12 has antiviral, anti-inflammatory and antifungal activity, supported in over 20 studies on human subjects.

Benefits:

Clinical studies have shown that Loroblis® contributes to the maintenance and development of a microbial flora with a protective role in the oral cavity and pharynx, with the potential to:

Improvement of manifestations associated with upper respiratory tract infections – 1 tablet/day, 90 days (especially in the cold season)
Improvement of manifestations associated with oral inflammatory diseases – 1 tablet/day, 30 days
Composition: 1 orodispersible tablet LOROBLIS® contains at least 1×10⁹ CFU Streptococcus salivarius K12 (BLIS® K12) + vitamin D3/ cholecalciferol (200 IU)

Method of administration: 1 tablet/day, in the evening after oral hygiene, minimum 3 months (especially in the cold season and before the start of the school year)

For children over 3 years old and adults.

Precautions:

The administration is done in the evening, after oral hygiene, without consuming liquids or food;
It is useless to administer it concomitantly with the antibiotic;
Contraindicated in immunocompromised patients, with chemotherapy, radiotherapy, severe leukopenia
Presentation form: box with 16 orodispersible tablets.